{"id":"albuterol-hfa-mdi","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Headache"},{"rate":"3-8%","effect":"Nervousness/anxiety"},{"rate":"2-5%","effect":"Palpitations"},{"rate":"2-5%","effect":"Muscle cramps"},{"rate":"1-3%","effect":"Throat irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Albuterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and rapid airway dilation, relieving bronchoconstriction. The HFA (hydrofluoroalkane) formulation is a propellant system used in metered-dose inhalers (MDI) for pulmonary delivery.","oneSentence":"Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:39.962Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm relief in asthma"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance and acute symptom relief"},{"name":"Exercise-induced bronchoconstriction prevention"}]},"trialDetails":[{"nctId":"NCT06563102","phase":"PHASE4","title":"Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-11","conditions":"Mild Asthma","enrollment":101},{"nctId":"NCT06502366","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-22","conditions":"Asthma","enrollment":422},{"nctId":"NCT04901715","phase":"EARLY_PHASE1","title":"Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-06-10","conditions":"Primary Ciliary Dyskinesia","enrollment":27},{"nctId":"NCT06154304","phase":"PHASE3","title":"BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2023-12-06","conditions":"Bronchial Asthma","enrollment":120},{"nctId":"NCT04912596","phase":"NA","title":"Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma","status":"RECRUITING","sponsor":"Intech Biopharm Ltd.","startDate":"2022-08-15","conditions":"Mild Asthma","enrollment":148},{"nctId":"NCT06618105","phase":"PHASE3","title":"Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd","status":"NOT_YET_RECRUITING","sponsor":"Macleods Pharmaceuticals Ltd","startDate":"2024-10-15","conditions":"Mild Asthma","enrollment":144},{"nctId":"NCT00070707","phase":"PHASE4","title":"Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-03","conditions":"Rhinitis, Allergic, Seasonal, Asthma","enrollment":188},{"nctId":"NCT06139991","phase":"PHASE1","title":"Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-16","conditions":"Heathy Participants","enrollment":66},{"nctId":"NCT01471340","phase":"PHASE4","title":"A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-01-09","conditions":"Asthma","enrollment":11744},{"nctId":"NCT02741271","phase":"PHASE3","title":"Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-05-11","conditions":"Asthma","enrollment":181},{"nctId":"NCT04803734","phase":"NA","title":"Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2021-03-19","conditions":"Healthy","enrollment":60},{"nctId":"NCT05300087","phase":"NA","title":"Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2022-02-24","conditions":"Healthy","enrollment":60},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT00530062","phase":"PHASE4","title":"Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-07-25","conditions":"Asthma","enrollment":49},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT01056159","phase":"PHASE1","title":"A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-01","conditions":"Asthma","enrollment":47},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT05152355","phase":"PHASE4","title":"Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2019-04-22","conditions":"Asthma","enrollment":270},{"nctId":"NCT00054964","phase":"PHASE2","title":"Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2003-03-31","conditions":"Asthma","enrollment":14},{"nctId":"NCT00085774","phase":"PHASE3","title":"Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-06-30","conditions":"Exercise-induced Bronchospasm","enrollment":24},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT00577655","phase":"PHASE3","title":"Albuterol HFA MDI in Pediatric Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-08","conditions":"Asthma","enrollment":103},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":"Persistent Asthma","enrollment":273},{"nctId":"NCT01058863","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-02","conditions":"Asthma","enrollment":72},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT02584257","phase":"PHASE3","title":"Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2016-04","conditions":"Mild Persistent Asthma","enrollment":217},{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1025},{"nctId":"NCT03364608","phase":"PHASE2","title":"Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-15","conditions":"Asthma","enrollment":86},{"nctId":"NCT03371459","phase":"PHASE2","title":"Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-29","conditions":"Asthma","enrollment":46},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19},{"nctId":"NCT03643874","phase":"PHASE2","title":"Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"Concentrx Pharmaceuticals, Inc.","startDate":"2018-06-30","conditions":"Asthma","enrollment":13},{"nctId":"NCT03373409","phase":"PHASE1","title":"Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI","status":"COMPLETED","sponsor":"Concentrx Pharmaceuticals, Inc.","startDate":"2017-11-30","conditions":"Asthma","enrollment":12},{"nctId":"NCT02045953","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-29","conditions":"Asthma","enrollment":21},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT03480997","phase":"PHASE1","title":"Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD","status":"COMPLETED","sponsor":"Pneuma Respiratory, Inc","startDate":"2016-12-27","conditions":"COPD","enrollment":46},{"nctId":"NCT01189396","phase":"PHASE2","title":"Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2010-07","conditions":"Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":27},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT00384189","phase":"PHASE3","title":"A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Asthma","enrollment":1080},{"nctId":"NCT02466347","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-06","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT02150499","phase":"PHASE3","title":"A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-07","conditions":"Asthma","enrollment":18},{"nctId":"NCT02466503","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-08","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT02162784","phase":"PHASE2","title":"Efficacy Study of SYN006 HFA MDI in Asthma Patients","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2013-02","conditions":"Asthma","enrollment":39},{"nctId":"NCT01019694","phase":"PHASE3","title":"Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":470},{"nctId":"NCT00809757","phase":"PHASE3","title":"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-12","conditions":"Asthma","enrollment":197},{"nctId":"NCT02173678","phase":"PHASE1","title":"Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT00818454","phase":"PHASE2","title":"4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-12","conditions":"Asthma","enrollment":226},{"nctId":"NCT00909779","phase":"PHASE3","title":"Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT00096616","phase":"PHASE2","title":"Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-11","conditions":"Asthma","enrollment":113},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT01302587","phase":"","title":"A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-03","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema","enrollment":306},{"nctId":"NCT00583986","phase":"PHASE3","title":"Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-09","conditions":"Asthma, Chronic Obstructive Pulmonary Disease, COPD","enrollment":150},{"nctId":"NCT00685347","phase":"PHASE2","title":"Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma, Bronchoconstriction","enrollment":33},{"nctId":"NCT00684866","phase":"PHASE2","title":"Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT00685022","phase":"PHASE2","title":"Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-06","conditions":"Asthma","enrollment":49},{"nctId":"NCT00684827","phase":"PHASE2","title":"A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-10","conditions":"Asthma","enrollment":32},{"nctId":"NCT00064389","phase":"PHASE3","title":"Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma","enrollment":746},{"nctId":"NCT00268723","phase":"PHASE3","title":"Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-12","conditions":"Exercise-induced Bronchospasm","enrollment":15},{"nctId":"NCT00685425","phase":"PHASE3","title":"Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-10","conditions":"Asthma, Bronchoconstriction","enrollment":62},{"nctId":"NCT01255579","phase":"PHASE4","title":"Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2007-07","conditions":"Bronchial Asthma","enrollment":10},{"nctId":"NCT00448435","phase":"PHASE3","title":"Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Bronchial Asthma","enrollment":51},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"BLOOD SODIUM INCREASED"},{"count":1,"reaction":"BLOOD UREA INCREASED"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"DEHYDRATION"},{"count":1,"reaction":"HYPOTENSION"},{"count":1,"reaction":"RENAL FAILURE CHRONIC"},{"count":1,"reaction":"RHABDOMYOLYSIS"},{"count":1,"reaction":"SEPSIS"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Albuterol","ProAir"],"phase":"marketed","status":"active","brandName":"Albuterol-HFA-MDI","genericName":"Albuterol-HFA-MDI","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation. Used for Acute bronchospasm relief in asthma, Chronic obstructive pulmonary disease (COPD) maintenance and acute symptom relief, Exercise-induced bronchoconstriction prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}